Company intelligence / Profile preview

TimeBio

Suwon-si, Gyeonggi-do, Republic of Koreatimebioventures.com ↗

Ownership: Private
Development stage: Commercial

Overview

No clinical trial results published. The company is developing an exosome-based platform targeting skin aging from immune dysfunction, with commercialized cosmetic products already available.

Therapeutic areas: DermatologyImmunology
Modalities: Exosome-based drug delivery therapyImmune-enhancing adjuvant (Biologic)Small molecule (for cosmetics/hair products)
Industry: Biotech

Drug pipeline

3 assets

GrabHair

Commercial

Indications: Hair loss

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on TimeBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TimeBio.

Explore the full profile